Oocyte donation
Oocyte donation is widely practiced worldwide, and since its introduction, almost 30 years ago, has become an extremely efficient therapeutic approach for both pre- and postmenopausal women who are in need of donor eggs. Like any other field in medicine, and in particular, reproductive medicine, many of the current practices associated with donor and recipient preparation and treatment have not been standardized. The purpose of the current survey is to explore current trends, practices and various issues related to donor and recipient evaluation and treatment.
The survey is conducted by Dr. Ariel Weissman, Wlfson Institute, IVF Center, Israel
- No
- Screening for genetic disease
- Karyotype
- Both 2+3 :Screening for genetic disease and Karyotype
- Only according to the egg recipient’s request
- Not involved in genetic testing
- Long GnRH agonist protocol
- Short GnRH agonist protocol
- GnRH antagonist protocol
- Other
- Not involved in stimulation protocols
- Human chorionic gonadotropin (hCG)
- GnRH agonist
- Either 1 or 2, individualized, according to the magnitude of response
- Not involved in ovulation triggering
- Younger than 30 years old
- Younger than 33 years old
- Younger than 35 years old
- Younger than 38 years old
- Younger than 40 years old
- No age limit
- Not involved in donor recruitment
- Fresh donation
- Frozen (banked) donation
- Anonymous
- Known donors
- GnRH agonist suppression
- Oral contraceptive pill
- 1+2 : GnRH agonist suppression and oral contraceptive pill
- None
- Oral
- Transdermal
- Vaginal
- Intramuscular
- None of the above
- Vaginal
- Intramuscular
- Oral
- None of the above
- Yes
- No
- Yes
- No
- Yes
- No
- >5 mm
- >6 mm
- >7 mm
- >8 mm
- > 9 mm
- > 10 mm
- No minimum
- Standard IVF
- ICSI
- Individualized, according to sperm quality and past information
- Until b-hCG is positive
- Until demonstration of a fetal heartbeat (6 weeks)
- 8 gestational weeks
- 10 gestational weeks
- 12 gestational weeks